Evaluation of functional magnetic resonance APT and DKI imaging for breast cancer

This study aimed to compare the performance of amide proton transfer-weighted imaging (APTWI) and diffusion kurtosis imaging (DKI) in differentiating benign from malignant breast lesions, evaluate molecular subtypes of breast cancer, and determine the diagnostic efficacy of the quantitative magnetic resonance imaging (qMRI) parameters in differentiating benign from malignant breast diseases.

The study included 168 women who underwent breast APTWI and DKI at Yunnan Cancer Hospital between December 2022 and July 2023. The APT signal intensity (SI), apparent kurtosis coefficient (Kapp), non-Gaussian diffusion coefficient (Dapp), and apparent diffusion coefficient (ADC) values were measured before surgery. The differences in the aforementioned qMRI parameters in molecular subtypes of breast cancer were analyzed using one-way analysis of variance. The efficacy of each quantitative parameter in differentiating benign from malignant breast diseases was evaluated using the receiver-operating characteristic curve.

Significant differences in qMRI parameters were noted between benign and malignant breast lesions. The Kapp (P < .0001) and APT (P < .05) values were higher for malignant tumors than for benign lesions. Conversely, the ADC (P < .0001) and Dapp (P < .0001) values were lower for malignant tumors than for benign lesions. The diagnostic performance was assessed using the area under the curve (AUC) for various parameter combinations. The AUC of Kapp was 0.871, Dapp was 0.872, APT SI was 0.643, DKI + APT was 0.893, DKI + ADC was 0.936, APT + ADC was 0.925, and DKI + APT + ADC was 0.933. Additionally, ADC values (P = .01) demonstrated superior diagnostic performance compared to Kapp (P = .03), Dapp (P = .03), and APT values (P = .06) in distinguishing between different molecular subtypes of breast cancer.

APTWI distinguished benign from malignant breast disease and enhanced the utility of diffusion-weighted MRI. However, it was not superior to DKI and DWI in identifying the molecular subtypes of breast cancer.